The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institute markets.
- Within the type category, adeno-associated virus is expected to witness higher growth over the forecast period due to the high safety profile and gene therapy demand.
- Within the end use category, pharmaceutical & biopharmaceutical is expected to witness the highest growth over the forecast period due to the rising biologics and advanced therapy development.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding biopharmaceutical manufacturing and research infrastructure.
Emerging Trends in Viral Vector Manufacturing Market
A shift in the viral vector manufacturing market is expected between 2025 and 2027, with more repeatable commercial-scale production. Growth will continue with the approval of more cell and gene therapies. In the meantime, manufacturers will increase their capacity and invest in process control and analytics. Lucintel expects continued growth, but pricing pressure and capacity constraints will continue.- Standardization of Platforms: Modular workflows for AAV and lentiviral vector production, coupled with faster turnaround times for single-use bioreactors, will decrease the time it takes to develop and transfer processes over the next 3-5 years.
- Automation and Analytics: A greater understanding of the process and FDA guidance will help manufacture closed systems for real-time monitoring of viral vector production. Automation and analytics will improve batch-to-batch consistency of viral vector production.
- Decentralization of Capacity: Decentralization of viral vector production will continue in North America and Europe, but the long-term viability of new capacity will depend on how the capacity is utilized.
- Quality By Design: Pharmaceutical developers are placing a greater emphasis on the attributes of the active pharmaceutical ingredient (APIs), such as empty-to-full capsid ratio and residual DNA. Increasing stringency in the release testing will result in higher upfront costs, protect commercial dependability, and ensure brand integrity of biologics.
- Cost-efficient Sustainability: Continuous improvements to single use bioprocessing systems reduce process requirement and increase flexibility; however, these improvements, along with increasing prices of raw materials, will have greater impact when combatted with Payers (i.e. insurance companies) scrutinizing the prices of treatments.
Recent Developments in the Viral Vector Manufacturing Market
Between 2025 and 2027, the viral vector manufacturing market is expected to grow due to the advancement of gene therapy pipelines toward commercial supply. At this time, sponsors will also be seeking manufacturing capacity in regional locations. According to Lucintel, 2023 saw an increase in investment for manufacturing capacities beyond pilot suites. Process control and regulatory readiness were the main factors considered when selecting a manufacturing supplier.- Capacity Expansion: In 2025, Thermo Fisher’s viral vector manufacturing network spanned more than 20 locations worldwide. Ongoing investment in commercial-scale suites is expected to increase competition for distributed supply and accelerated technology transfer.
- Consolidation: Also in 2025, a leading contract manufacturer reported more than 100 viral vector programs. Integration of development and commercial services is expected to continue.
- Automation: In 2025, automation in processing platforms reduced batch process times by up to 30%. Further adoption of automation in AAV manufacturing is expected to improve productivity and reproducibility.
- Regional Manufacturing: In July 2025, developers from Europe and North America announced the construction of bioreactor facilities of more than 2000 L. The construction of larger local manufacturing plants will ease the current dependence on international logistics for the transport of biologics, as well as meet local needs for reimbursement and supply.
- Analytics Investment: In September 2025, suppliers in the industry launched assays that shortened timelines for release testing by approximately 50%. Refinement and characterization of biologics will aid regulatory submissions and reduce the time biologics are under a hold and the working capital tied to inventory.
Strategic Growth Opportunities in the Viral Vector Manufacturing Market
The viral vector manufacturing market is shifting from bespoke clinical supply to repeatable commercial capacity. Lucintel expects the majority of cell and gene therapy candidates that will reach late-stage development between 2024 and 2026, to require stronger assurances of comparability and supply. They will track this shift as investments move to regional facilities, automation and specialized services.- Commercial-scale CDMO Capacity: In January 2025, more than 2,000 gene therapy studies were conducted globally. As candidates progress and sponsors advance multiple indications, the demand for a flexible multi-product manufacturing capacity will increase.
- Non-viral and Hybrid Platforms: In March 2025, several sponsors progressed lipid nanoparticle (LNP) and other non-viral and hybrid technologies along with their viral vector programs. These hybrid technologies will gain interest over the next five years if they enable lower immunogenicity, larger payloads, and ease of revaccination.
- Regional Manufacturing: In April 2025, the European Union had more than 35 of Advanced Therapy Medicinal Products approved. There will be greater on-shoring of vector production in alignment with government policies to reduce import dependencies and improve supply chain security and resiliency.
- Automated Quality Control: In May 2025, we saw more than 1,000 active cell and gene therapy programs in regulatory filings. Technologies that allow for closed processing with lower deviation risk and better process comparability across sites will continue to gain traction and warrant a higher price.
- Sustainable Process Inputs: In February 2025, single-use systems represented over 80% of bioprocessing system installations. Suppliers of single-use systems that enhance process and manufacturing sustainability with lower process waste, improved energy efficiency, and ease of purification will command more interest. Customers will prioritize total manufacturing emissions in their procurement decisions.
Viral Vector Manufacturing Market Drivers and Challenges
The viral vector manufacturing market is influenced by a number of factors including rapid technology changes, increasing demand for advanced therapies, and investments made in the market. Similarly, the requirements and expectations of regulatory agencies continue to raise the bar for comparability and quality. Concurrently, developers of these therapies seek faster and lower cost methods of manufacturing to meet market demands. In this context, Lucintel expects strategic expansion of manufacturing capacities and continuous innovations to be the key drivers of the market over the next 3-5 years. Beyond this time frame, we anticipate that the market will experience the impacts of the high and rapid growth demands of increasingly complicated therapeutic products, while simultaneously needing to balance the requirements of reliable, steady-state production and compliance.The factors responsible for driving this market include:
- Increased Adoption of Cell and Gene Therapies: The expansion of the market for cell and gene therapies continues to fuel the growth of adeno-associated viral, lentiviral, and other vectors. It is expected that between 40-50 cell and gene therapies will be launched by 2025 in the major markets. New product candidates will continue to fuel the market for manufacturing, and product-specific requirements will increase the need for flexible facilities and specialized personnel.
- Advances in Technology: Improved automation and closed processes along the bioprocessing chain led to a decrease in contamination and an increase in process efficiencies. Single-use technologies dominated the bioprocessing market and are expected to continue to do so. Advances in technologies to improve batch processes will enable manufacturers to produce smaller batch sizes and address the market needs for personalized therapies for rare diseases more efficiently.
- Regulatory Support: Better regulatory direction for vector characterization and potency, and for sterility and comparability assessments, is helping agencies clarify what they expect, and are therefore helping to guide investment in qualified manufacturing capacity. During 2025, regulators in the United States and Europe released guidance and review decisions for advanced therapy products, and as such validated analytical methods became increasingly important. Regulatory standardization in the next three to five years will help reduce uncertainty, facilitate technology transfer, and build assurance in outsourcing manufacturing partners.
- Capacity Expansion and Infrastructure Investment: Continued demand for commercial-scale vector production has prompted Pharma, and Contract Development and Manufacturing Organizations (CDMOs) to build new specialized facilities. In 2025, multiple industry plans for advanced therapy manufacturing capacities ran in the hundreds of millions of dollars. Improving the supply of facilities and locations for commercial manufacturing will alleviate pressure on the current manufacturing facilities and benefit larger clinical trials.
- Product Innovation and Cost Optimization: To further improve a vector’s efficacy and reduce cost per dose, iterative design changes of vectors, cell lines and plasmids are being made. In 2025, many industry process development initiatives focused on incremental improvements in vector productivity. Continued product and process innovation will make advanced therapy products more accessible by improving their commercial viability.
The challenges facing this market include:
- High Manufacturing Costs: In 2025, it is anticipated that manufacturing and quality-control costs will make up more than 20% of the development costs for advanced therapies. Challenges will continue to influence the market due to the need for process intensification, outsourcing, standardized platforms, and improved efficiency of analytical workflows to enable affordable dosing for greater access by patients.
- Complex Processes and Scalability: The scale up from small-scale lab production to large-scale commercial production can affect vector quality, potency, and purity. In 2025, several developers were still reporting process development timelines in excess of 12 months before they were ready for large-scale commercial manufacturing. This challenge is expected to impact the market over the next 3 to 5 years and will affect the advancement of clinical programs due to process scalability and consistency. This can result in batch failures and limit the ability of manufacturers to serve both small-scale personalized therapies and larger, more commercialized indications.
- Uncertainty in The Supply Chain and Regulations: Dependence on specialized plasmids, cell banks, resins, single-use components, and testing services creates supply-chain risks. In 2025, the lead times for critical manufacturing materials included several months, particularly for customized materials. Dual sourcing and production in the region will be encouraged. The market will also promote the use of larger supply buffers and the implementation of more stringent supplier qualification processes. Regulatory differences between countries will continue to complicate technology transfers and limit the commercialization of certain processes.
List of Viral Vector Manufacturing Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies viral vector manufacturing market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the viral vector manufacturing market companies profiled in this report include:
- Merck
- Lonza
- Fujifilm Diosynth Biotechnologies
- Thermo Fisher Scientific
- Cobra Biologics
- Catalent
- Wuxi Biologics
- Takara Bio
- Waisman Biomanufacturing
- Genezen Laboratories
Viral Vector Manufacturing Market by Segment
The study includes a forecast for the global viral vector manufacturing market by type, workflow, application, end use, and region.Type [Value ($M) from 2019 to 2035]:
- Adenovirus
- Retrovirus
- Adeno-Associated Virus
- Lentivirus
- Plasmid DNA
- Others
Workflow [Value ($M) from 2019 to 2035]:
- Upstream Manufacturing
- Downstream Manufacturing
Application [Value ($M) from 2019 to 2035]:
- Cell & Gene Therapy
- Vaccinology
- Research & Other Applications
End Use [Value ($M) from 2019 to 2035]:
- Pharmaceutical & Biopharmaceutical
- Research Institutes
- Others
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Viral Vector Manufacturing Market
As expectations for quality, comparability and supply resilience increase, the viral vector manufacturing market is entering a capacity-building phase. Between 2025 and 2027, investments will be focused on process automation, modular facilities and regional production. Lucintel’s research revealed that these focus areas will be shaping supplier strategies in the upcoming years.- United States: Within the U.S., focus is on developing domestic capacity and standardizing regulatory frameworks. Thermo Fisher accelerated its investments in the U.S. manufacturing and research of biopharmaceuticals with an expected $2 billion spend over 4 years starting in 2025. This investment focused on reinforcing its supply of viral vectors and support the commercial launch of cell and gene therapies.
- China: China is utilizing industrial policies to fund the expansion of local manufacturing. In March 2025, WuXi AppTec announced continued investments to advance its cell and gene therapy platforms and its viral-vector manufacturing facilities. These investments provide domestic supply of cell and gene therapy manufacturing and give Chinese sponsors the means to advance their programs without relying on overseas contract manufacturers.
- Germany: Similar to China, Germany is also utilizing industrial policies to support manufacturing infrastructure and frameworks. In June 2025, Boehringer Ingelheim invested in its cell and gene therapy business to further build its viral-vector manufacturing capabilities to reinforce its European commercial supply.
- India: The public and private sectors in India are making efforts to improve local biologics. The Department of Biotechnology continues to implement the BioE3 policy in January 2025. This policy promotes the development of biopharmaceutical manufacturing facilities and addresses advanced therapy products.
- Japan: The public and private sectors in Japan are also making efforts to strengthen the local manufacturing of biologics. In April 2025, Takara Bio continued its investment to develop its GMP-grade cell and gene therapy manufacturing facility to provide viral vector services in Japan.
Features of the Global Viral Vector Manufacturing Market
- Market Size Estimates: viral vector manufacturing market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($M).
- Regional Analysis: viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, workflow, application, end use, and regions for the viral vector manufacturing market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Merck
- Lonza
- FUJIFILM Diosynth Biotechnologies
- Thermo Fisher Scientific
- Cobra Biologics
- Catalent
- Wuxi Biologics
- Takara Bio
- Waisman Biomanufacturing
- Genezen laboratories
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

